Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a responseguided therapy strategy  

作　　者：Pei-Xin Zhang Xiao-Wei Zheng Ya-Fei Zhang Jun Ye Wei Li Qian-Qian Tang Jie Zhu Gui-Zhou Zou Zhen-Hua Zhang 

机构地区：[1]Department of Infectious Diseases,The Second Affiliated Hospital of Anhui Medical University,Hefei 230601,Anhui Province,China [2]Department of Infectious Diseases,Anhui Provincial Hospital,Hefei 230000,Anhui Province,China [3]Department of Hepatology,The Second People’s Hospital of Fuyang City,Fuyang 236000,Anhui Province,China

出　　处：《World Journal of Hepatology》2024年第3期405-417,共13页世界肝病学杂志（英文版）（电子版）

基　　金：Supported by the Anhui Provincial Natural Science Foundation,No.2108085MH298;the Scientific Research Project of the Second Affiliated Hospital of Anhui Medical University,No.2019GMFY02 and 2021lcxk027;the Scientific Research Project of Colleges and Universities in Anhui Province,No.KJ2021A0323.

摘　　要：BACKGROUND Models for predicting hepatitis B e antigen(HBeAg)seroconversion in patients with HBeAg-positive chronic hepatitis B(CHB)after nucleos(t)ide analog treatment are rare.AIM To establish a simple scoring model based on a response-guided therapy(RGT)strategy for predicting HBeAg seroconversion and hepatitis B surface antigen(HBsAg)clearance.METHODS In this study,75 previously treated patients with HBeAg-positive CHB underwent a 52-week peginterferon-alfa(PEG-IFNα)treatment and a 24-wk follow-up.Logistic regression analysis was used to assess parameters at baseline,week 12,and week 24 to predict HBeAg seroconversion at 24 wk post-treatment.The two best predictors at each time point were used to establish a prediction model for PEG-IFNαtherapy efficacy.Parameters at each time point that met the corresponding optimal cutoff thresholds were scored as 1 or 0.RESULTS The two most meaningful predictors were HBsAg≤1000 IU/mL and HBeAg≤3 S/CO at baseline,HBsAg≤600 IU/mL and HBeAg≤3 S/CO at week 12,and HBsAg≤300 IU/mL and HBeAg≤2 S/CO at week 24.With a total score of 0 vs 2 at baseline,week 12,and week 24,the response rates were 23.8%,15.2%,and 11.1%vs 81.8%,80.0%,and 82.4%,respectively,and the HBsAg clearance rates were 2.4%,3.0%,and 0.0%,vs 54.5%,40.0%,and 41.2%,respectively.CONCLUSION We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNαtherapy.

关 键 词：Chronic hepatitis B Hepatitis B e antigen-positive Peginterferon-alfa Prediction model Response-guided therapy strategy 

分 类 号：R512.62[医药卫生—内科学]